On November 19, Palantir rose 3.4% in Regular Trading, trading at $165.44 per share, with turnover of $269 million.
The move was associated with improving sentiment after Palantir’s England NHS Federated Data Platform contract was extended through 2029, alongside reported commercial order progress that reinforced expectations for medium-term demand stability.
Recent market coverage indicated Palantir will continue participating in the NHS project through 2029, while additional commentary highlighted expanding commercial traction, including new orders and the fact that U.S. commercial revenue has surpassed U.S. government revenue. This more constructive fundamental backdrop appears to have outweighed a cautious options setup seen earlier in the session, when a $17.09 million in-the-money put structure dominated block flow and reflected lingering hedging or bearish positioning.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments